Abstract:Machiko Matsumoto-Sasaki, 1 Kaoruko Simizu, 1 Masanobu Suzuki, 2 Masaru Suzuki, 1 Hirokazu Kimura, 1 Yuji Nakamaru, 2 Yoichi M Ito, 3 Akihiro Honma, 2 Satoshi Konno 1 1 Department of Respiratory Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan; 2 Department of Otolaryngology-Head and Neck Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan; 3 Data Science Center, Promotion Unit, Institute of Health Science Innovation for Medical Care, Hokkaido University Hospital, Sapporo, Japan Correspondence: Kaoruko Simizu, Department of Respiratory Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Kita 15, Nishi 7, Kita-ku, Sapporo, Japan, Tel +81-11-706-5911, Fax +81-11-706-7899, Email Purpose: Biologics have been used increasingly for the treatment of severe asthma. However, established guidelines for the selection, switching, or discontinuation of biologics do not exist. We aimed to identify the clinical characteristics of patients with asthma who required switching biologics and the factors associated with switching biologics. Patients and Methods: This was a retrospective study of 42 patients with severe asthma treated with biologics at the Hokkaido University Hospital between 23 rd June 2016 and 30 th April 2021, when two biologics were available in Japan. We compared the characteristics of subjects who continued and switched biologics. The time to switch the biologics was assessed by type 2 inflammatory biomarkers, pulmonary function indices, and the presence of comorbidities, including the Japanese Epidemiological Survey of Refractory Eosinophilic Chronic Rhinosinusitis (JESREC) score and aspirin exacerbated respiratory diseases (AERD), using the Kaplan–Meier method and a multivariate Cox proportional hazards model. Results: Eight and five patients were treated by mepolizumab and benralizumab at baseline, respectively among the 31% (13/42) who switched the biologics. Subjects who required switching biologics were characterized by high blood eosinophil counts, younger age, JESREC scores of 11 points or higher, and AERD. The time taken to switch biologics was significantly shorter in the subgroups with high JESREC scores (≥ 11) or AERD, compared with their counterparts with low JESREC scores or without AERD (both, P < 0.05). JESREC scores of ≥ 11, but not the presence of AERD, were associated with time to switch biologics. Conclusion: The presence of eosinophilic chronic rhinosinusitis based on JESREC scores of ≥ 11 and younger age were factors associated with switching biologics in asthma. Keywords: aspirin-exacerbated respiratory disease, asthma, biologics, comorbidities, eosinophilic chronic rhinosinusitis Biologic therapies have played a significant role in the treatment of severe asthma. 1 "Difficult-to-treat asthma is asthma that is uncontrolled, despite receiving medium or high dose Inhaled corticosteroids (ICS)-long-acting beta2-agonist (LABA) treatment or requires high dose ICS-LABA treatment to maintain adequate symptom control and reduce exacerbations, which incorrect inhalation technique, poor adherence to the medication, smoking, comorbidities, or misdiagnosis may concern. Severe asthma is a subset of difficult-to-treat asthma that is uncontrolled despite adherence to maximal optimal therapy and treatment of contributory factors or worsens when the dosage of the medication is decreased. 2,3 Poor asthma control is defined as an Asthma Control Test (ACT) score of 19 or less. 4 Symptom control, frequency of exacerbations, and pulmonary function should be evaluated in the course of treatment including biologics. 2 In Japan, four types of biologics are currently in use. 5 There are no established guidelines for the use of different biologics, 2,5–7 although some reports suggest that type 2 markers such as blood eosinophil counts, fractional exhaled nitric oxide (FeNO), and IgE could act as eligibility criteria for selecting biologic therapy. Practically, there is substantial overlap in the proposed indications for biologics, which leaves the ultimate decision at the discretion of the treating clinician. Thus, some patients have to discontinue, which requires amelioration to achieve optimal treatment. The definitions of responders have been applied to evaluate the efficacy of biologics. 8 However, these definitions have not been validated. Eger et al defined patients who achieved ≥50% reduction in exacerbations as responders and ≥50% reduction in prednisolone dose as a response to bio -Abstract Truncated-

A comparison of treatment response to biologics in asthma-COPD overlap and pure asthma: Findings from the PRISM study

The Response to Biologics is Better in Patients with Severe Asthma Than in Patients with Asthma–COPD Overlap Syndrome

Response to Various Biologics in Patients with Both Asthma and Chronic Obstructive Pulmonary Disease

Real-World Effectiveness of Biologics in Patients With Severe Asthma: Analysis of the KoSAR

Real-world biologics response and super-response in the International Severe Asthma Registry cohort

Exploring Definitions and Predictors of Response to Biologics for Severe Asthma

Effect of biologic therapies on quality of life in severe asthma: Findings from the PRISM study

Association between pre-biologic T2-Biomaker combinations and response to biologics in patients with severe asthma

Biologics in T2 Severe Asthma: Unveiling Different Effectiveness by Real-World Indirect Comparison

Smaller differences in the comparative effectiveness of biologics in reducing asthma-related hospitalizations compared to overall exacerbations.

Impact of pre-biologic impairment on meeting domain-specific biologic responder definitions in patients with severe asthma

Temporal variation in the effectiveness of biologics in asthma: Effect modification by changing patient characteristics

Comparison of clinical remission criteria for severe asthma patients receiving biologic therapy

Comparative Impact of Asthma Biologics – A Nationwide US Claim-Based Analysis

Differences in asthma-related outcomes by anti-IL-5 biologics, omalizumab, and dupilumab based on blood eosinophil counts

Clinical Characteristics of Patients and Factors Associated with Switching Biologics in Asthma

How I do it. Choosing the right biologic for the right patient with severe asthma

Precision Medicine Intervention in Severe Asthma (PRISM) study: molecular phenotyping of patients with severe asthma and response to biologics

Suboptimal response to biologics in severe asthma patients with humoral immunodeficiencies

Response to Biologic Therapy in Patients with Asthma and Reduced Pulmonary Diffusion Capacity

Effects of biologics in obese severe asthmatic patients